SEER PROGRAM (NATIONAL CANCER INSTITUTE (U.S.))
\sˈi͡ə pɹˈə͡ʊɡɹam nˈaʃənə͡l kˈansəɹ ˈɪnstɪtjˌuːt jˌuːˈɛs], \sˈiə pɹˈəʊɡɹam nˈaʃənəl kˈansəɹ ˈɪnstɪtjˌuːt jˌuːˈɛs], \s_ˈiə p_ɹ_ˈəʊ_ɡ_ɹ_a_m__ n_ˈa_ʃ_ə_n_əl k_ˈa_n_s_ə_ɹ ˈɪ_n_s_t_ɪ_t_j_ˌuː_t__ j_ˌuː_ˈɛ_s]\
Sort: Oldest first
-
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
By DataStellar Co., Ltd
Word of the day
Platidiam
- An inorganic water-soluble platinum complex. After undergoing hydrolysis, it reacts DNA produce both intra interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity cisplatin correlates with cellular arrest in G2 phase cell cycle.